A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP)

BACKGROUND: The standard 6-month four-drug regimen for the treatment of drug-sensitive tuberculosis has remained unchanged for decades and is inadequate to control the epidemic. Shorter, simpler regimens are urgently needed to defeat what is now the world’s greatest infectious disease killer. METHOD...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:BMC Med
Hoofdauteurs: Phillips, Patrick P. J., Dooley, Kelly E., Gillespie, Stephen H., Heinrich, Norbert, Stout, Jason E., Nahid, Payam, Diacon, Andreas H., Aarnoutse, Rob E., Kibiki, Gibson S., Boeree, Martin J., Hoelscher, Michael
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: BioMed Central 2016
Onderwerpen:
Research Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4804526/
https://ncbi.nlm.nih.gov/pubmed/27004726
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12916-016-0597-3
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items